EA201590085A1 - Антитела анти-egfr и их применение - Google Patents
Антитела анти-egfr и их применениеInfo
- Publication number
- EA201590085A1 EA201590085A1 EA201590085A EA201590085A EA201590085A1 EA 201590085 A1 EA201590085 A1 EA 201590085A1 EA 201590085 A EA201590085 A EA 201590085A EA 201590085 A EA201590085 A EA 201590085A EA 201590085 A1 EA201590085 A1 EA 201590085A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- egfr
- antibodies
- present
- bind
- application
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
В настоящем изобретении предлагаются антитела, связывающие EGFR, а также способы их применения. В соответствии с некоторыми осуществлениями настоящего изобретения антителами являются полностью человеческие антитела, которые связываются с человеческим EGFR с высокой аффинностью. В некоторых осуществлениях антитела настоящего изобретения способны ингибировать рост клеток опухоли, экспрессирующих высокие уровни EGFR, и/или индуцировать антителозависимую клеточно-опосредованную цитотоксичность (ADCC) таких клеток. Антитела настоящего изобретения применяются для лечения различных форм рака, а также других нарушений, связанных с EGFR.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261663984P | 2012-06-25 | 2012-06-25 | |
| US201361821000P | 2013-05-08 | 2013-05-08 | |
| PCT/US2013/047476 WO2014004427A2 (en) | 2012-06-25 | 2013-06-25 | Anti-egfr antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201590085A1 true EA201590085A1 (ru) | 2015-04-30 |
| EA030421B1 EA030421B1 (ru) | 2018-08-31 |
Family
ID=48782632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201590085A EA030421B1 (ru) | 2012-06-25 | 2013-06-25 | Антитела анти-egfr и их применение |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9132192B2 (ru) |
| EP (1) | EP2864357B1 (ru) |
| JP (1) | JP6486268B2 (ru) |
| KR (1) | KR20150023387A (ru) |
| CN (1) | CN104411722B (ru) |
| AR (1) | AR091545A1 (ru) |
| AU (2) | AU2013280610B2 (ru) |
| BR (1) | BR112014029099A2 (ru) |
| CA (1) | CA2876697C (ru) |
| CL (1) | CL2014003465A1 (ru) |
| CO (1) | CO7160093A2 (ru) |
| EA (1) | EA030421B1 (ru) |
| ES (1) | ES2816645T3 (ru) |
| HK (1) | HK1206040A1 (ru) |
| IL (1) | IL235392B (ru) |
| MX (1) | MX356329B (ru) |
| MY (2) | MY181086A (ru) |
| NZ (1) | NZ701633A (ru) |
| PH (1) | PH12014502437B1 (ru) |
| SG (3) | SG10201804151QA (ru) |
| TW (2) | TW201843172A (ru) |
| UY (1) | UY34876A (ru) |
| WO (1) | WO2014004427A2 (ru) |
| ZA (1) | ZA201407927B (ru) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014CN03042A (ru) | 2011-09-30 | 2015-07-03 | Regeneron Pharma | |
| US9273143B2 (en) * | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
| US9840560B2 (en) * | 2013-03-15 | 2017-12-12 | Alper Biotech Llc | Monoclonal antibodies to EGFR, and uses therefor |
| SG11201607109QA (en) | 2014-02-28 | 2016-09-29 | Merus Nv | Antibodies that bind egfr and erbb3 |
| SI3143042T1 (sl) * | 2014-05-16 | 2020-08-31 | Ablynx N.V. | Variabilne domene imunoglobulina |
| KR20230145503A (ko) | 2014-05-16 | 2023-10-17 | 아블린쓰 엔.브이. | 개선된 면역글로불린 가변 도메인 |
| TW202330904A (zh) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| CN105017424B (zh) * | 2015-08-31 | 2021-02-09 | 北京泱深生物信息技术有限公司 | 一种egfr抗体可变区及其应用 |
| DK3365373T3 (da) | 2015-10-23 | 2021-04-06 | Merus Nv | Bindingsmolekyler, der hæmmer cancervækst |
| MA43416A (fr) | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| IL269656B1 (en) | 2017-03-31 | 2024-02-01 | Merus Nv | Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene |
| KR20210084695A (ko) | 2017-07-06 | 2021-07-07 | 리제너론 파마슈티칼스 인코포레이티드 | 당단백질을 만들기 위한 세포 배양 과정 |
| MA49846A (fr) * | 2017-08-09 | 2020-06-17 | Merus Nv | Anticorps qui se lient à l'egfr et à cmet |
| WO2019114793A1 (zh) * | 2017-12-13 | 2019-06-20 | 凯惠科技发展(上海)有限公司 | 一种egfr抗体及其制备方法和应用 |
| CA3084059A1 (en) | 2017-12-22 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
| EP3746471A1 (en) | 2018-01-31 | 2020-12-09 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing size and charge variant drug product impurities |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| JP2021514609A (ja) | 2018-02-28 | 2021-06-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ウイルス混入物質を同定するためのシステムおよび方法 |
| CN111801351A (zh) * | 2018-03-14 | 2020-10-20 | 豪夫迈·罗氏有限公司 | 抗体亲和力成熟的方法 |
| IL307577A (en) | 2018-03-19 | 2023-12-01 | Regeneron Pharma | In-house capillary electrophoresis tests and reagents |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| CN108680746A (zh) * | 2018-06-05 | 2018-10-19 | 中国科学院合肥物质科学研究院 | 一种控制肺癌细胞活力的分子靶标及其应用 |
| CA3100035A1 (en) | 2018-08-27 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Use of raman spectroscopy in downstream purification |
| US11754569B2 (en) | 2018-08-30 | 2023-09-12 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| ES2942024T3 (es) | 2019-01-16 | 2023-05-29 | Regeneron Pharma | Métodos para caracterizar enlaces disulfuro |
| MX2021011500A (es) * | 2019-03-22 | 2021-10-22 | Regeneron Pharma | Anticuerpos multiespecificos egfr x cd28. |
| US20200363400A1 (en) | 2019-05-13 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Competitive Ligand Binding Assays |
| CN113993544A (zh) * | 2019-07-24 | 2022-01-28 | 神州细胞工程有限公司 | 用于治疗egfr高表达的癌症的多变剂量方法 |
| WO2021061790A1 (en) | 2019-09-24 | 2021-04-01 | Regeneron Pharmaceuticals, Inc. | Systems and methods for chromatography use and regeneration |
| KR20220104797A (ko) | 2019-11-25 | 2022-07-26 | 리제너론 파마슈티칼스 인코포레이티드 | 비수성 에멀전을 이용한 지속 방출 제형 |
| EP4085253B1 (en) | 2020-01-21 | 2024-03-13 | Regeneron Pharmaceuticals, Inc. | Deglycosylation methods for electrophoresis of glycosylated proteins |
| BR112022017048A2 (pt) | 2020-02-26 | 2022-11-16 | Vir Biotechnology Inc | Anticorpos contra sars-cov-2 e métodos para usar os mesmos |
| CN116209772A (zh) | 2020-08-31 | 2023-06-02 | 瑞泽恩制药公司 | 用于提高细胞培养性能和减少天冬酰胺序列变体的天冬酰胺补料策略 |
| AU2021385363A1 (en) | 2020-11-25 | 2023-06-08 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| AU2021401301A1 (en) | 2020-12-17 | 2023-08-03 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| EP4281542A1 (en) | 2021-01-20 | 2023-11-29 | Regeneron Pharmaceuticals, Inc. | Methods of improving protein titer in cell culture |
| WO2022187323A1 (en) | 2021-03-03 | 2022-09-09 | Regeneron Pharmaceuticals, Inc. | Systems and methods for quantifying and modifying protein viscosity |
| BR112023018665A2 (pt) | 2021-03-26 | 2023-10-03 | Regeneron Pharma | Métodos e sistemas para desenvolvimento de protocolos de mistura |
| WO2022240757A1 (en) | 2021-05-10 | 2022-11-17 | Entrada Therapeutics, Inc. | Antigen-binding and antigen degradation constructs |
| WO2022256383A1 (en) | 2021-06-01 | 2022-12-08 | Regeneron Pharmaceuticals, Inc. | Micropchip capillary electrophoresis assays and reagents |
| US20230077710A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS |
| TW202328179A (zh) | 2021-09-20 | 2023-07-16 | 美商再生元醫藥公司 | 控制抗體異質性之方法 |
| TW202331252A (zh) | 2021-10-07 | 2023-08-01 | 美商再生元醫藥公司 | Ｐｈ計校準與校正 |
| US20230116199A1 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
| WO2023076340A1 (en) | 2021-10-26 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
| CN116333119B (zh) * | 2021-12-16 | 2024-02-23 | 徕特康(苏州)生物制药有限公司 | 抗表皮生长因子受体抗体及其制备方法和用途 |
| US20230296559A1 (en) | 2022-03-18 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
| WO2024015418A1 (en) | 2022-07-13 | 2024-01-18 | Regeneron Pharmaceuticals, Inc. | Mild acid immunoassays for detection of analytes |
| WO2024076926A1 (en) | 2022-10-03 | 2024-04-11 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies |
| CN117430707B (zh) * | 2023-10-25 | 2024-04-19 | 重庆天科雅生物科技有限公司 | 一种cik细胞的制备方法及其在治疗癌症中的用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
| AU2071695A (en) | 1994-03-17 | 1995-10-03 | Merck Patent Gmbh | Anti-EGFR single-chain FVS and anti-EGFR antibodies |
| US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| US20020173629A1 (en) | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7638598B2 (en) * | 2001-04-06 | 2009-12-29 | The Trustees Of The University Of Pennsylvania | ErbB interface peptidomimetics and methods of use thereof |
| IL159225A0 (en) | 2001-06-13 | 2004-06-01 | Genmab As | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| WO2003012072A2 (en) * | 2001-08-03 | 2003-02-13 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbb family members and methods of use thereof |
| BR0312534A (pt) * | 2002-07-15 | 2007-03-13 | Genentech Inc | método de identificação de um tumor, método para a identificação de células de tumor, método para prever a resposta de um indivìduo diagnosticado com um tumor de her2-positivo, método para a identificação de um individuo responsivo ao tratamento com anticorpo anti-her2 e métodos de tratamento de um paciente e artigo de manufatura |
| US8323987B2 (en) * | 2004-02-17 | 2012-12-04 | The University Of North Carolina At Chapel Hill | Modulation of epidermal growth factor heterodimer activity |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| JP2009511032A (ja) * | 2005-10-11 | 2009-03-19 | アブリンクス エン．ヴェー． | Ｅｇｆｒおよびｉｇｆ−ｉｒに対するナノボディおよびポリペプチド |
| CA2629095A1 (en) * | 2005-11-12 | 2007-05-24 | Eli Lily And Company | Anti-egfr antibodies |
| US7498142B2 (en) | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| NZ602675A (en) * | 2008-03-18 | 2014-03-28 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| TWI496582B (zh) * | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| SG174378A1 (en) * | 2009-03-20 | 2011-10-28 | Genentech Inc | Bispecific anti-her antibodies |
| JP5612663B2 (ja) * | 2009-04-07 | 2014-10-22 | ロシュ グリクアート アクチェンゲゼルシャフト | 二重特異性抗ＥｒｂＢ−１／抗ｃ−Ｍｅｔ抗体 |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| WO2011156617A2 (en) * | 2010-06-09 | 2011-12-15 | Aveo Pharmaceuticals, Inc. | Anti-egfr antibodies |
-
2013
- 2013-06-20 TW TW107129255A patent/TW201843172A/zh unknown
- 2013-06-20 TW TW102121841A patent/TWI641619B/zh not_active IP Right Cessation
- 2013-06-25 WO PCT/US2013/047476 patent/WO2014004427A2/en active Application Filing
- 2013-06-25 MY MYPI2017704291A patent/MY181086A/en unknown
- 2013-06-25 SG SG10201804151QA patent/SG10201804151QA/en unknown
- 2013-06-25 NZ NZ701633A patent/NZ701633A/en not_active IP Right Cessation
- 2013-06-25 UY UY34876A patent/UY34876A/es unknown
- 2013-06-25 CN CN201380033859.6A patent/CN104411722B/zh not_active Expired - Fee Related
- 2013-06-25 SG SG10201610590UA patent/SG10201610590UA/en unknown
- 2013-06-25 AR ARP130102231 patent/AR091545A1/es unknown
- 2013-06-25 MX MX2014014361A patent/MX356329B/es active IP Right Grant
- 2013-06-25 EP EP13735519.4A patent/EP2864357B1/en active Active
- 2013-06-25 MY MYPI2014003097A patent/MY164604A/en unknown
- 2013-06-25 SG SG11201407163XA patent/SG11201407163XA/en unknown
- 2013-06-25 KR KR20147035064A patent/KR20150023387A/ko not_active Application Discontinuation
- 2013-06-25 US US13/925,923 patent/US9132192B2/en active Active
- 2013-06-25 EA EA201590085A patent/EA030421B1/ru not_active IP Right Cessation
- 2013-06-25 BR BR112014029099A patent/BR112014029099A2/pt not_active Application Discontinuation
- 2013-06-25 AU AU2013280610A patent/AU2013280610B2/en active Active
- 2013-06-25 ES ES13735519T patent/ES2816645T3/es active Active
- 2013-06-25 CA CA2876697A patent/CA2876697C/en active Active
- 2013-06-25 JP JP2015518639A patent/JP6486268B2/ja active Active
-
2014
- 2014-10-29 IL IL235392A patent/IL235392B/en active IP Right Grant
- 2014-10-30 ZA ZA2014/07927A patent/ZA201407927B/en unknown
- 2014-10-30 PH PH12014502437A patent/PH12014502437B1/en unknown
- 2014-12-19 CL CL2014003465A patent/CL2014003465A1/es unknown
- 2014-12-24 CO CO14283133A patent/CO7160093A2/es unknown
-
2015
- 2015-07-13 HK HK15106655.6A patent/HK1206040A1/xx unknown
- 2015-08-06 US US14/820,324 patent/US9789184B2/en active Active
-
2017
- 2017-09-11 US US15/700,665 patent/US20180036405A1/en not_active Abandoned
-
2018
- 2018-07-05 AU AU2018204895A patent/AU2018204895A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201590085A1 (ru) | Антитела анти-egfr и их применение | |
| EA201400625A1 (ru) | Антитела против pd-l1 и их применение | |
| PH12018500363A1 (en) | Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof | |
| EA201890453A1 (ru) | Анти-angptl8 антитела и их применение | |
| EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
| MX2022008523A (es) | Compuestos que interactuan con glicanos y metodos de uso. | |
| EA201891331A1 (ru) | Бипаратопные полипептиды - антагонисты передачи сигнала wnt в опухолевых клетках | |
| EA201891268A1 (ru) | Соединения, которые можно применять в качестве ингибиторов киназы | |
| EA201790413A1 (ru) | Антитела против tigit | |
| NZ743124A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| PH12015501493B1 (en) | Anti-pdgfr-beta antibodies and uses thereof | |
| EA201590987A1 (ru) | Соединения и способы их применения | |
| EA201590997A1 (ru) | Соединения и способы их применения | |
| EA201391416A1 (ru) | Новые соединения в качестве модуляторов протеинкиназ | |
| EA201390756A1 (ru) | Модулирующие nk-клетки терапии и способы для лечения гематологических злокачественных заболеваний | |
| EA201791393A2 (ru) | АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ | |
| WO2017079570A3 (en) | Splise-switching oligonucleotides and methods of use | |
| JO3547B1 (ar) | أجسام مضادة ضد تخليق جدار الخلية واستعمالاتها | |
| EA201892225A1 (ru) | АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ | |
| MX2015008534A (es) | COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS. | |
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
| WO2019112978A3 (en) | Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| EA201370196A1 (ru) | Антитела, которые связывают фактор роста опухоли-альфа и эпирегулин | |
| EA201791389A1 (ru) | Способы и композиции антител, направленных против bmp6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM RU |